Harvard Bioscience Management
Management criteria checks 1/4
Harvard Bioscience's CEO is Jim Green, appointed in Jul 2019, has a tenure of 4.83 years. total yearly compensation is $2.39M, comprised of 24.5% salary and 75.5% bonuses, including company stock and options. directly owns 4.33% of the company’s shares, worth $7.18M. The average tenure of the management team and the board of directors is 1.8 years and 6.6 years respectively.
Key information
Jim Green
Chief executive officer
US$2.4m
Total compensation
| CEO salary percentage | 24.5% |
| CEO tenure | 4.8yrs |
| CEO ownership | 4.3% |
| Management average tenure | 1.8yrs |
| Board average tenure | 6.6yrs |
Recent management updates
Recent updates
Even With A 25% Surge, Cautious Investors Are Not Rewarding Harvard Bioscience, Inc.'s (NASDAQ:HBIO) Performance Completely
Dec 22
Harvard Bioscience, Inc.'s (NASDAQ:HBIO) Intrinsic Value Is Potentially 60% Above Its Share Price
Sep 23Harvard Bioscience, Inc. (NASDAQ:HBIO) Stock's 25% Dive Might Signal An Opportunity But It Requires Some Scrutiny
Aug 10An Intrinsic Calculation For Harvard Bioscience, Inc. (NASDAQ:HBIO) Suggests It's 23% Undervalued
Apr 26Here's Why Harvard Bioscience (NASDAQ:HBIO) Can Afford Some Debt
Apr 11Harvard Bioscience GAAP EPS of $0.05 beats by $0.06, revenue of $29.2M misses by $1.2M
Aug 04Harvard Bioscience (NASDAQ:HBIO) Takes On Some Risk With Its Use Of Debt
Jun 08Harvard Bioscience - Dressed Up And Waiting For A Suitor
Mar 15Here's Why Harvard Bioscience (NASDAQ:HBIO) Can Manage Its Debt Responsibly
Feb 16Is Harvard Bioscience (NASDAQ:HBIO) Using Too Much Debt?
Nov 04Is Harvard Bioscience, Inc. (NASDAQ:HBIO) Trading At A 37% Discount?
Oct 01An Intrinsic Calculation For Harvard Bioscience, Inc. (NASDAQ:HBIO) Suggests It's 25% Undervalued
May 04These 4 Measures Indicate That Harvard Bioscience (NASDAQ:HBIO) Is Using Debt Extensively
Apr 19Analysts Are Optimistic We'll See A Profit From Harvard Bioscience, Inc. (NASDAQ:HBIO)
Apr 04Have Insiders Sold Harvard Bioscience, Inc. (NASDAQ:HBIO) Shares Recently?
Mar 20What Kind Of Shareholders Hold The Majority In Harvard Bioscience, Inc.'s (NASDAQ:HBIO) Shares?
Mar 07Harvard Bioscience (NASDAQ:HBIO) Shareholders Have Enjoyed A 92% Share Price Gain
Feb 17An Intrinsic Calculation For Harvard Bioscience, Inc. (NASDAQ:HBIO) Suggests It's 35% Undervalued
Feb 02
Have Insiders Been Buying Harvard Bioscience, Inc. (NASDAQ:HBIO) Shares This Year?
Jan 15Harvard Bioscience: Wait For The Green Shoots Of Improvement
Jan 12When Will Harvard Bioscience, Inc. (NASDAQ:HBIO) Become Profitable?
Dec 28Is Harvard Bioscience (NASDAQ:HBIO) Using Too Much Debt?
Dec 11At US$3.78, Is Harvard Bioscience, Inc. (NASDAQ:HBIO) Worth Looking At Closely?
Nov 26Harvard Bioscience, Inc. 2020 Q3 - Results - Earnings Call Presentation
Nov 08CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2023 | US$2m | US$586k | -US$3m |
| Sep 30 2023 | n/a | n/a | -US$3m |
| Jun 30 2023 | n/a | n/a | -US$5m |
| Mar 31 2023 | n/a | n/a | -US$2m |
| Dec 31 2022 | US$2m | US$574k | -US$10m |
| Sep 30 2022 | n/a | n/a | -US$7m |
| Jun 30 2022 | n/a | n/a | -US$4m |
| Mar 31 2022 | n/a | n/a | -US$6m |
| Dec 31 2021 | US$3m | US$574k | -US$288k |
| Sep 30 2021 | n/a | n/a | -US$2m |
| Jun 30 2021 | n/a | n/a | -US$3m |
| Mar 31 2021 | n/a | n/a | -US$4m |
| Dec 31 2020 | US$3m | US$574k | -US$8m |
| Sep 30 2020 | n/a | n/a | -US$7m |
| Jun 30 2020 | n/a | n/a | -US$8m |
| Mar 31 2020 | n/a | n/a | -US$7m |
| Dec 31 2019 | US$3m | US$265k | -US$5m |
| Sep 30 2019 | n/a | n/a | -US$2m |
| Jun 30 2019 | n/a | n/a | US$432k |
| Mar 31 2019 | n/a | n/a | -US$819k |
| Dec 31 2018 | US$153k | n/a | -US$4m |
| Sep 30 2018 | n/a | n/a | -US$8m |
| Jun 30 2018 | n/a | n/a | -US$8m |
| Mar 31 2018 | n/a | n/a | -US$7m |
| Dec 31 2017 | US$129k | n/a | -US$2m |
Compensation vs Market: Jim's total compensation ($USD2.39M) is above average for companies of similar size in the US market ($USD1.64M).
Compensation vs Earnings: Jim's compensation has increased whilst the company is unprofitable.
CEO
Jim Green (65 yo)
4.8yrs
Tenure
US$2,392,240
Compensation
Mr. James W. Green, also known as Jim, has been the Chairman of Harvard Bioscience, Inc. since June 5, 2017 and its Director since April 30, 2015. He serves as President and Chief Executive Officer of Harv...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 4.8yrs | US$2.39m | 4.33% $ 7.2m | |
| CFO & Treasurer | 1.3yrs | US$571.27k | 0.097% $ 160.9k | |
| Senior Vice President of Operations | 1.8yrs | no data | no data | |
| Chief Legal Counsel & Corporation Secretary | 1.8yrs | no data | no data | |
| Senior Vice President of Global Sales | less than a year | no data | no data | |
| Vice President of Global People Operations | no data | no data | no data |
1.8yrs
Average Tenure
62yo
Average Age
Experienced Management: HBIO's management team is not considered experienced ( 1.8 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 9.1yrs | US$2.39m | 4.33% $ 7.2m | |
| Independent Director | 4.7yrs | US$213.09k | 0.47% $ 773.5k | |
| Lead Independent Director | 9.5yrs | US$223.06k | 1.08% $ 1.8m | |
| Independent Director | 6.6yrs | US$205.45k | 0.52% $ 855.2k | |
| Independent Director | 6.6yrs | US$198.09k | 0.55% $ 915.6k |
6.6yrs
Average Tenure
57yo
Average Age
Experienced Board: HBIO's board of directors are considered experienced (6.6 years average tenure).